176 related articles for article (PubMed ID: 35117786)
1. Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.
Wei W; Ding Y; He J; Wu J
Transl Cancer Res; 2020 Jul; 9(7):4173-4187. PubMed ID: 35117786
[TBL] [Abstract][Full Text] [Related]
2. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.
Hu J; Tian R; Ma Y; Zhen H; Ma X; Su Q; Cao B
Front Oncol; 2021; 11():645245. PubMed ID: 34123795
[TBL] [Abstract][Full Text] [Related]
5. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis.
Sun YM; Li W; Chen ZY; Wang Y
Front Oncol; 2021; 11():651553. PubMed ID: 34745932
[TBL] [Abstract][Full Text] [Related]
6. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
7. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
Front Oncol; 2021; 11():662731. PubMed ID: 34221977
[TBL] [Abstract][Full Text] [Related]
8. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Petrelli F; Morelli AM; Luciani A; Ghidini A; Solinas C
Target Oncol; 2021 Sep; 16(5):553-568. PubMed ID: 34224061
[TBL] [Abstract][Full Text] [Related]
9. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
11. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
13. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
14. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
[TBL] [Abstract][Full Text] [Related]
15. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Yang W; Men P; Xue H; Jiang M; Luo Q
Front Oncol; 2020; 10():197. PubMed ID: 32211312
[No Abstract] [Full Text] [Related]
16. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
[TBL] [Abstract][Full Text] [Related]
17. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
18. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
19. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Wang DY; Ye F; Zhao S; Johnson DB
Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
[No Abstract] [Full Text] [Related]
20. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
